MedPath

Adanate, Inc.

Adanate, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2018-01-01
Employees
1
Market Cap
-
Website
http://adanate.com

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Solid Tumor, Adult
Interventions
Drug: PD(L)-1 inhibitor
First Posted Date
2022-11-01
Last Posted Date
2025-01-28
Lead Sponsor
Adanate, Inc
Target Recruit Count
46
Registration Number
NCT05601219
Locations
🇺🇸

HonorHealth, Scottsdale, Arizona, United States

🇺🇸

Florida Cancer Specialists, Orlando, Florida, United States

🇺🇸

Duke University, Durham, North Carolina, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath